Glenmark said the nasal spray was designed to kill Coronavirus in the upper airways, prevent it from incubation and spread to the lungs.

Pharmacy Glenmark said on Monday it has signed an agreement with the Canadian Biotech Company Sanada Research and Development Corp to commercialize its nose spray for Covid-19 treatment in India and other Asian countries. Under exclusive long-term strategic partnerships, Glenmark and Sanotize will produce, market and distribute nitric oxide nasal spray (Nons) in India, Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Sri Lanka, Myanmar, Timor Leste Vietnam, according to a statement by Indian company.

The Chair and Managing Director of Pharmaceutical Glenmark Glenn Saldanha said the partnership with the Sanotize reflected a glenmark-focused approach to Covid-19 and would help reduce the burden of pandemics in the region.

“It also marks the opportunity in our valuable licenses in our main therapy from respiratory medicine, as well as the possibility of supplying products globally for Sanotize and its partners outside our territory,” Saldanha said in a statement. “Glenmark will ensure timely and widespread access to this effective nasal spray, which we hope will bring very much needed assistance for patients in all regions and a wider world,” he added.

“In joining Glenmark, Sanotize can accelerate efforts to have nasal antivirus sprays available as own managed defense lines, the first defense against Covid-19 during the current pandemic and to help prevent the outbreak in the future,” Regev, CEO and Co-Founder Sanotize, said in the statement.

According to Glenmark Pharmaceuticals, the nasal spray is designed to kill Coronavirus in the upper airways, prevent it from incubation and spread to the lungs. This is based on nitrate oxide (no) and has a direct effect on SARS-COV-2, a virus that causes Covid-19.

The Sanotize clinical trial shows in March this year that Nons is an antivirus treatment that is safe and effective to prevent Covid-19 transmission, shorten the road, and reduce the severity of the symptoms. Non reduces the average viral load of around 95 percent in the first 24 hours and then with more than 99 percent within 72 hours. It has been tested on healthy volunteers and patients as part of the English and Canadian clinical trials, said the company.

Pharmacy Glenmark said in July this year that the company presented a proposal to the Expert Committee for the subject of the central drug control organization (CDSCO) for emergency approval for the import and marketing of nasal spray.

“The Committee has recommended phase III clinical trials that will be carried out in Indian patients in weeks to be followed. Phase III clinical trials for Nons are expected to be completed, followed by commercial launches under the name of the Fabispray brand in India, on the fourth quarter of the year calendar 2021, “added Pharmacy Glenmark.